IN2013DE03085A - - Google Patents

Info

Publication number
IN2013DE03085A
IN2013DE03085A IN3085DE2013A IN2013DE03085A IN 2013DE03085 A IN2013DE03085 A IN 2013DE03085A IN 3085DE2013 A IN3085DE2013 A IN 3085DE2013A IN 2013DE03085 A IN2013DE03085 A IN 2013DE03085A
Authority
IN
India
Prior art keywords
manufacturing
ophthalmic
formulation
present
pharmaceutical
Prior art date
Application number
Other languages
English (en)
Inventor
V Shah Mandar
Bahri Deepak
Original Assignee
Sentiss Pharma Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentiss Pharma Private Ltd filed Critical Sentiss Pharma Private Ltd
Priority to EA201690532A priority Critical patent/EA030535B1/ru
Priority to PCT/IB2014/065262 priority patent/WO2015056149A1/en
Priority to UAA201603600A priority patent/UA116273C2/uk
Priority to EP14811969.6A priority patent/EP3057576A1/en
Priority to US15/028,930 priority patent/US9801813B2/en
Priority to IN3085DE2013 priority patent/IN2013DE03085A/en
Priority to CA2924562A priority patent/CA2924562A1/en
Publication of IN2013DE03085A publication Critical patent/IN2013DE03085A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3085DE2013 2013-10-17 2014-10-13 IN2013DE03085A (enrdf_load_stackoverflow)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA201690532A EA030535B1 (ru) 2013-10-17 2014-10-13 Не содержащий консерванта офтальмологический фармацевтический состав
PCT/IB2014/065262 WO2015056149A1 (en) 2013-10-17 2014-10-13 Preservative-free ophthalmic pharmaceutical formulation
UAA201603600A UA116273C2 (uk) 2013-10-17 2014-10-13 Офтальмологічний фармацевтичний склад, що не містить консерванта
EP14811969.6A EP3057576A1 (en) 2013-10-17 2014-10-13 Preservative-free ophthalmic pharmaceutical formulation
US15/028,930 US9801813B2 (en) 2013-10-17 2014-10-13 Preservative-free ophthalmic pharmaceutical formulation
IN3085DE2013 IN2013DE03085A (enrdf_load_stackoverflow) 2013-10-17 2014-10-13
CA2924562A CA2924562A1 (en) 2013-10-17 2014-10-13 Preservative-free ophthalmic pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3085DE2013 IN2013DE03085A (enrdf_load_stackoverflow) 2013-10-17 2014-10-13

Publications (1)

Publication Number Publication Date
IN2013DE03085A true IN2013DE03085A (enrdf_load_stackoverflow) 2015-04-24

Family

ID=52023563

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3085DE2013 IN2013DE03085A (enrdf_load_stackoverflow) 2013-10-17 2014-10-13

Country Status (7)

Country Link
US (1) US9801813B2 (enrdf_load_stackoverflow)
EP (1) EP3057576A1 (enrdf_load_stackoverflow)
CA (1) CA2924562A1 (enrdf_load_stackoverflow)
EA (1) EA030535B1 (enrdf_load_stackoverflow)
IN (1) IN2013DE03085A (enrdf_load_stackoverflow)
UA (1) UA116273C2 (enrdf_load_stackoverflow)
WO (1) WO2015056149A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230143595A1 (en) * 2020-03-31 2023-05-11 Sentiss Pharma Private Limited A sterilization process of timolol gel forming solution through aseptic filtration
US12186430B2 (en) 2020-04-07 2025-01-07 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
EP4281040A4 (en) * 2021-01-21 2024-11-27 Kowa Company, Ltd. Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis
CN112920138B (zh) * 2021-01-27 2023-03-07 成都摩尔生物医药有限公司 一种噻吗洛尔杂质的制备方法
KR102808906B1 (ko) 2021-06-18 2025-05-19 대우제약 주식회사 고점도 점안제를 무균여과하는 방법
EP4309644A1 (en) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Preservative-free ophthalmic composition comprising an antiglaucoma agent
AU2023338294A1 (en) * 2022-09-07 2025-03-20 Combangio, Inc. Preparation and purification methods for mesenchymal stem cell derived secretome
CN116139151B (zh) * 2022-12-22 2025-02-11 武汉科福新药有限责任公司 一种含有噻吗洛尔的局部用药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438123A (en) * 1980-03-04 1984-03-20 Merck & Co., Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4797413A (en) 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4731368A (en) 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation
US4847289A (en) 1987-06-08 1989-07-11 Merck & Co., Inc. Thiophene sulfonamide antiglaucoma agents
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
IE911192A1 (en) 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
IT1395044B1 (it) 2009-06-30 2012-09-05 Marzoli Spa Apritoio a flusso assiale
TW201109325A (en) * 2009-07-30 2011-03-16 Wakamoto Pharma Co Ltd Aqueous composition for eye drops
MX2012006401A (es) * 2009-12-03 2012-07-10 Lupin Ltd Proceso para preparar composiciones oftalmicas farmaceuticas.

Also Published As

Publication number Publication date
EP3057576A1 (en) 2016-08-24
CA2924562A1 (en) 2015-04-23
UA116273C2 (uk) 2018-02-26
EA030535B1 (ru) 2018-08-31
EA201690532A1 (ru) 2016-09-30
US20160235665A1 (en) 2016-08-18
US9801813B2 (en) 2017-10-31
WO2015056149A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
IN2013DE03085A (enrdf_load_stackoverflow)
MY171920A (en) Prevention and treatment of ocular conditions
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX351230B (es) Formulacion oftalmica y metodo para mitigar la presbicia.
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012051575A3 (en) Device for ocular access
MX377727B (es) Solución oftálmica acuosa y método para tratar el síndrome del ojo seco.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
IN2014CN03123A (enrdf_load_stackoverflow)
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
EA201301332A1 (ru) ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
PH12012501271A1 (en) Topical ophthalmic peptide formulation
MX362854B (es) Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
EA201500669A1 (ru) Офтальмологическая фармацевтическая композиция для наружного применения, содержащая регорафениб
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2016007795A (es) Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.
MX2015009414A (es) Agentes analgesicos oculares topicos.